Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1963735 | 0.80 | MAPT (0.54) | MEN1KMT2ATDP1HSP90AA1POLB | |
| SCHEMBL2161013 | 0.78 | MAPK1 (0.52) | MEN1KMT2ATDP1HSP90AA1POLB | |
| SCHEMBL1964353 | 0.78 | MEN1 (0.54) | MEN1KMT2ATDP1HSP90AA1POLB | |
| SCHEMBL12418543 | 0.77 | MEN1 (0.58) | MEN1KMT2ATDP1HSP90AA1POLB | |
| SCHEMBL515394 | 0.77 | MEN1 (0.53) | MEN1KMT2ATDP1HSP90AA1POLB | |
| SCHEMBL3700015 | 0.76 | MEN1 (0.49) | MEN1KMT2ATDP1HSP90AA1POLB | |
| SCHEMBL12394775 | 0.74 | MEN1 (0.56) | MEN1KMT2ATDP1HSP90AA1POLB | |
| SCHEMBL10364639 | 0.74 | MEN1 (0.57) | MEN1KMT2ATDP1HSP90AA1POLB | |
| SCHEMBL1966218 | 0.73 | MEN1 (0.48) | MEN1KMT2ATDP1HSP90AA1POLB | |
| SCHEMBL12418678 | 0.73 | MEN1 (0.56) | MEN1KMT2ATDP1HSP90AA1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172095-A1 | Triazole Compounds, Use Thereof and Agents Containing Same | BASF SE (DE) | 2011-07-14 | — | — | US | disclosed |
| EP-2334656-A1 | TRIAZOLE COMPOUNDS, USE THEREOF, AND AGENTS CONTAINING SAME | BASF SE (DE) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010029001-A1 | TRIAZOLE COMPOUNDS, USE THEREOF, AND AGENTS CONTAINING SAME | BASF SE (DE) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172095-A1 | Triazole Compounds, Use Thereof and Agents Containing Same | CYP3A43, CYP3A5, CYP1B1 | MEN1 953/4885KMT2A 2578/4885TDP1 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.